Journal
PHARMACOGENOMICS
Volume 18, Issue 18, Pages 1671-1682Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0115
Keywords
apoptosis; BCL2; microRNA-509-3p; ovarian cancer
Categories
Funding
- National Natural Science Foundation of China [81572567, J1310025]
Ask authors/readers for more resources
Aim: Previous observations have implicated miR-509-3p's ability in regulating cisplatin-triggered apoptosis in ovarian cancer. However, the underlying mechanisms were not fully understood. Materials & methods: The roles of miR-509-3p in cellular apoptosis were assessed through MTT and DAPI assays. The confirmation of the regulation of BCL2 family members by miR-509-3p was investigated by luciferase reporter assay, western blot, quantitative real-time PCR and rescue experiments. Results: MiR-509-3p can decrease the IC50 values of cisplatin and promote apoptosis in ovarian cancer cells. Furthermore, on a panel of antiapoptotic proteins, we identified that miR-509-3p could regulate BCL2, BCL2L2 and MCL1 via their 3'UTRs. Conclusion: Our study demonstrates that miR-509-3p could sensitize ovarian cancer cells to cisplatin treatment by targeting multiple anti-apoptosis genes including BCL2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available